# Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

> **NCT02658279** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Glioma
- Recurrent Malignant Glioma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02658279
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01-22
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658279, "Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02658279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*